Rexahn begins patient enrollment for depressive disorder study
The randomised, double blind and placebo-controlled study will enroll up to 300 patients, and will be conducted at 40 sites across the US. In the study, Serdaxin will
Mediar Therapeutics has announced a collaboration and option agreement with Ono Pharmaceutical to develop new treatments for fibro-inflammatory diseases.